TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of Subjects With a ≥ 2-grade Improvement on the Lateral Canthal Line
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of epinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma concentration of norepinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pathologic Complete Response (PCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Success rates for controlling apnea episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Iohexol clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of participants who experience a new grade 3 or greater adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants achieving post-treatment control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful urine collection on first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Biologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Total Neuropathy Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnosis of conductive hearing loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Peak Cold Pressor Tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Self-report Rating of Drug Effect (0-100)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peak Number Accurate on Circular Lights
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment compliance to CPAP or NIV
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: amount of intraoperative intra-ocular bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of novel bio markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of prebiotic bar
Endpoint domain: Adverse events/effects
Primary endpoint: Length of Cardiovascular-related Hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in Symptomatic Efficacy Domains (NYHA Class and MLWHFQ Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Brief Smell Identification Test (BSIT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety of intrathecal enzyme treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Compliance Percentage
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change From Baseline in Lissamine Green Staining (LGS) Total Score at Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Global Symptom Frequency (GSF) Total Score at Day 7
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Graded Redefined Assessment of Strength, Sensibility, and Prehension (GRASSP) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency and severity of all treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of subjects with corneal thickness decrease of at least 8% and or visual acuity improvement of at least 1 line
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: DYRK1A activity biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary concentration of paracetamol metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Knowledge, Attitude and Practice regarding post exposure prophylaxis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall cost of equipment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number and type of additional interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Duration of appointments
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of unplanned follow-ups
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: change in BOLD fMRI signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Anxiety and depression level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Duration of acid-pocket
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: AOFAS Foot-and-Ankle Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pulmonary capillary wedge pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to visualize cords
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neutralizing Antibody Seroconversion to Poliovirus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area under the concentration-time curve of the analyte in plasma at different time points (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach the maximum concentration of the analyte in plasma (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Rate of change in blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in the composite score on the Patient-Rated Tennis Elbow Evaluation (PRTEE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in NIH Stroke Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Barthel Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in modified Rankin Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Dynamic changes of PaO2/FiO2 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Volume of the Hippocampi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Efficacy of FlutiForm®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Bortezomib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HbA1C value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Dyspnea at VO2max
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Stimulation amplitude changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ECMP score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Pain evaluated by Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain evaluated by algometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain activity at rest and during emotional stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Severe Infusional Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Isometric knee-extension strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperational bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in taste disturbances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in smell disturbances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transfusion Independence Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: MRI brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Immune Suppression-free, Rejection-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Freedom From Left Ventricular Lead-Related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom From System-related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Responder Rate to Biventricular Pacing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of hours on sick leave
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement in stooling symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: TWA hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Patients Experiencing a Grade 3 or Above Treatment-Related Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Sustained Virological Response 12 Weeks Post Treatment (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fewer adverse cardiorespiratory events
Endpoint domain: Adverse events/effects
Primary endpoint: acute rejection reaction treated or confirmed by biopsy
Endpoint domain: Adverse events/effects
Primary endpoint: loss of graft
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Peripheral Neurotoxic Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of pleural biopsy methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of vaginal delivery within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Symptom Severity (neuropathy) - FACT-Tax tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom Severity (neuropathy) - EORTC QLQ-C30
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Symptom Severity (neuropathy) - MYCAW questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in the Itch Assessment Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose Area Under the Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Foot plantar pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Major Adverse Cardiovascular Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Positive or negative result of challenge test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft Survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary Lung Graft Dysfunction (PGD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of vessels fulfilling FFR and CFR criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Children's self-scale variables
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Management of emotional distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Aneurysm recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: biomarkers of rheumatic diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Model-derived population & individual PK parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Probability of Virologic Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: VAP-1 serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in visceral fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety and tolerability of pepinemab
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of pepinemab in Early Manifest HD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evidence of clinically definite Osteomyelitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Median 24-hour Intragastric pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean change of intra-patient global score of the VFQ-25
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants With Urodynamic Detrusor Overactivity Events or Prostatic Obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: false alarm rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % time with uninterrupted signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute and late toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Change of urinary albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change of urinary N-Acetyl-β-D-Glucosaminidase (NAG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change of urinary Kidney Injury Molecule-1 (KIM-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change of urinary Neutrophil gelatinase-associated lipocalin (NGAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change of urinary T-gelsolin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Laboratory Assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemodynamic parameter LV dP/dt(max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to Need for Inhaled or Intravenous (IV) Antipseudomonal Antibiotics
Endpoint domain: Adverse events/effects
Primary endpoint: Infections Per 1,000 (CAUTI) Days
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Proportion of Days Used Outside of Controlled Environment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Burden frequency
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Reliability of the AFAS scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Validity of the Upper Limb Motor Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Requiring Redo surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Complications (categorized as mild, moderate, severe)
Endpoint domain: Adverse events/effects
Primary endpoint: Concentration of moxifloxacin in liver tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anticipate deliveries number 48 hours in advance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Brief Negative Symptoms Scale (BNSS) Avolition/Apathy Subscore
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Brief Negative Symptoms Scale (BNSS) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion with S2AI screw abnormality on CT scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of SI Joint pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in self-reported SI joint pain at 2 years
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Composite of All Death, Target Vessel Myocardial Infarction (MI) and Stroke (MACCE)
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of ARC Definite or Probable Stent Thrombosis (ST)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Major Bleeding (GUSTO Classification)
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change in Serum LDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ratio DFG / VEC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Subsequent Cancer
Endpoint domain: Mortality/survival
Primary endpoint: Concordance with standard test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients able to achieve therapeutic target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of tobramycin in the burn population
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of distribution of tobramycin in the burn population
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical exercise tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of patients with at least a 50% reduction in abdominal pain days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction of surgical site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Warfarin Adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timeout of Target INR Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Responders Based on Clinician Global Impression-Anxiety Improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in LH/FSH Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Fruit and vegetable consumption
Endpoint domain: Life impact
Endpoint subdomain: Nutrition
Primary endpoint: Safety after primary administration of A/H1N1 vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Measurement of tooth widths
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of arch lengths
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of overjet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of overbite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of crown heights
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of labio lingual widths
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in loudness and pitch of tinnitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positivity for at least one islet autoantibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Clinical diagnosis of type 1 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: duration of absorption of persistent sub-foveal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to void spontaneously
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Inter-arch distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rescue medication usage
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Functional Goals
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Daily functioning- Self-Care
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Daily functioning- Mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: evolution of pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Requiring Medical Management
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Days Between NEC Diagnosis and Surgical Intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of NPO Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient/Caregiver Knowledge of Treatment Risks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient/Caregiver Knowledge of Treatment Benefits
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient/Caregiver Treatment Expectations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cmax of EE and DNG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-tlast of EE and DNG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean pre-nebulization bronchiolitis severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Reporting HDSS Score of 1 or 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acetylated Amantadine levels in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes